Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.75 |
| ▸ | GAK | O14976 | 3/20 | 0.75 |
| ▸ | FBP1 | P09467 | 2/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.61 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.61 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.61 |
| ▸ | BUB1 | O43683 | 2/20 | 0.61 |
| ▸ | STK10 | O94804 | 2/20 | 0.61 |
| ▸ | MAP3K1 | Q13233 | 2/20 | 0.61 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.61 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.61 |
| ▸ | ILK | Q13418 | 2/20 | 0.61 |
| ▸ | KDR | P35968 | 2/20 | 0.61 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.61 |
| ▸ | PLK4 | O00444 | 1/20 | 0.61 |
| ▸ | CIT | O14578 | 1/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.61 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13606820 | 0.95 | EGFR (0.73) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL14490025 | 0.95 | EGFR (0.72) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL14490026 | 0.95 | EGFR (0.72) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL13606819 | 0.90 | EGFR (0.77) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL13606815 | 0.90 | EGFR (0.77) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL13606812 | 0.90 | EGFR (0.77) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL13606814 | 0.90 | EGFR (0.77) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL29623603 | 0.89 | EGFR (0.75) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL14489992 | 0.89 | EGFR (0.75) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL185543 | 0.89 | EGFR (0.75) | EGFRGAKFBP1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 456 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682147-B1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM INT (DE) | 2009-10-07 | — | — | EP | claimed |
| US-20070037781-A1 | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-15 | — | — | US | claimed |
| US-20060178364-A1 | Use of EGFR tyrosinkinase inhibitors for treatment of chronic rhinosinusitis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-10 | — | — | US | claimed |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2005-10-27 | — | — | US | claimed |
| US-20050203088-A1 | Medicament combinations based on scopine- or tropene acid esters with EGFR-kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | claimed |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-04-04 | — | — | US | disclosed |
| CN-112279808-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-112250627-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| CN-110840847-B | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | 沃泰克斯药物股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-110713489-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-20060106013-A1 | PI3-kinases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-18 | — | — | US | disclosed |
| US-20060002863-A1 | Aerosol suspension formulations containing TG 227 ea or TG 134 a as propellant | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-05 | — | — | US | disclosed |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2005-10-27 | — | — | US | disclosed |
| US-20050209227-A1 | Novel long acting betamimetics for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-22 | — | — | US | disclosed |
| US-20050203088-A1 | Medicament combinations based on scopine- or tropene acid esters with EGFR-kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | disclosed |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-18 | — | — | US | disclosed |
| US-6924285-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2005-08-02 | — | — | US | disclosed |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209227-A1 | Novel long acting betamimetics for the treatment of respiratory diseases | ADRA1D, ADRB2, ADRA1A | EGFR 4212/4885GAK 4308/4885FBP1 3231/4885 |
| US-20070037781-A1 | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | ADRB2, ADRA2A, ADRB1 | EGFR 4088/4885GAK 4011/4885FBP1 3593/4885 |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | EGFR 1752/4885GAK 1735/4885FBP1 3924/4885 |
| US-20050203088-A1 | Medicament combinations based on scopine- or tropene acid esters with EGFR-kinase inhibitors | ERBB2, EGFR, ERBB3 | EGFR 2/4885GAK 586/4885FBP1 4057/4885 |
| US-20060106013-A1 | PI3-kinases | PIK3C3, PIK3CB, PIK3CD | EGFR 1106/4885GAK 277/4885FBP1 1458/4885 |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, MTNR1B | EGFR 3691/4885GAK 4053/4885FBP1 2460/4885 |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | EGFR 1752/4885GAK 1735/4885FBP1 3924/4885 |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | EGFR 1752/4885GAK 1735/4885FBP1 3924/4885 |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B2, CYP11B1, HPGD | EGFR 1233/4885GAK 1108/4885FBP1 1166/4885 |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B1, AR, CYP11B2 | EGFR 221/4885GAK 1085/4885FBP1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.